Fosamax FAERS Safety Signals

FDA Approval History and Early Post-Market Period

The FDA approved alendronate sodium (Fosamax) on October 22, 1995, for the treatment of osteoporosis in postmenopausal women, making it the first oral bisphosphonate available in the United States [1]. Merck subsequently obtained additional indications: prevention of postmenopausal osteoporosis (1997), glucocorticoid-induced osteoporosis (1999), osteoporosis in men (2000), and Paget's disease of bone [2]. The once-weekly 70 mg formulation, approved in 2000, became the dominant prescribed regimen.

Approval rested primarily on the Fracture Intervention Trial (FIT), a landmark randomized controlled trial enrolling 2,027 women aged 55 to 81 with at least one existing vertebral fracture. Over 36 months, alendronate 5 mg daily (increased to 10 mg at month 24) reduced hip fracture incidence by 51% (1.1% vs. 2.2%, relative hazard 0.49 to 95% CI 0.23 to 0.99) and clinical vertebral fractures by 55% compared with placebo [1]. The trial's adverse event profile was broadly reassuring, with gastrointestinal symptoms comparable between groups.

During the first post-market decade (1995 to 2005), FAERS accumulated reports primarily involving upper GI complaints: esophageal erosion, dysphagia, and gastric ulceration [3]. These early signals reinforced the strict dosing instructions already on the label, requiring patients to take alendronate with a full glass of water, remain upright for at least 30 minutes, and avoid lying down after dosing.

Atypical Femoral Fractures: The Defining Safety Signal

Atypical femoral fractures emerged as the most practice-changing FAERS signal for alendronate. These are stress fractures of the femoral shaft or subtrochanteric region occurring with minimal or no trauma. They differ from typical osteoporotic hip fractures both in location and mechanism.

The signal first appeared in case reports published between 2005 and 2007, and a 2008 report by Lenart et al. in the New England Journal of Medicine described 15 patients on long-term alendronate who sustained low-energy subtrochanteric fractures with characteristic radiographic features: transverse fracture lines, cortical thickening, and bilateral involvement in several cases [4]. The American Society for Bone and Mineral Research (ASBMR) convened a task force that published diagnostic criteria in 2010, defining AFFs by five major features including their location in the femoral diaphysis and a transverse or short oblique orientation [5].

A 2011 systematic review and meta-analysis by Schilcher et al. estimated the absolute risk at 3.2 to 50 cases per 100,000 person-years of bisphosphonate use, with risk increasing after 5 years of continuous therapy [6]. The relative risk compared with non-users ranged from 2.1 to 128 depending on the study and duration of exposure. The FDA responded in October 2010 with a drug safety communication requiring a new warning about AFFs on all bisphosphonate labels, including Fosamax [7].

The ASBMR task force's 2014 update stated: "The risk of atypical femoral fractures increases with longer duration of bisphosphonate exposure but declines after drug discontinuation" [5]. This finding directly informed the modern concept of a bisphosphonate drug holiday. The fracture risk from AFFs remains low in absolute terms. For every 100 hip fractures prevented by 3 years of alendronate therapy, approximately 1 AFF may occur, a ratio that shifts unfavorably only beyond 5 to 7 years of continuous use [8].

Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) represents the second major FAERS-driven safety signal for alendronate. ONJ involves exposed bone in the maxillofacial region persisting for more than 8 weeks in patients without a history of head and neck radiation.

The first case reports linking bisphosphonates to ONJ appeared in 2003, primarily in cancer patients receiving high-dose intravenous zoledronic acid or pamidronate [9]. FAERS reports for oral alendronate followed, though at substantially lower frequency. The FDA issued an updated label for Fosamax in 2005 adding ONJ as a reported adverse reaction.

The American Association of Oral and Maxillofacial Surgeons (AAOMS) estimated the incidence of ONJ in patients taking oral bisphosphonates for osteoporosis at 0.1% or roughly 1 in 1,000, far lower than the 1% to 15% rates observed in oncology patients on IV bisphosphonates [10]. A 2015 position paper from AAOMS clarified the definition and staging system, noting that "the risk of developing ONJ associated with oral bisphosphonate therapy for osteoporosis remains very low" [10].

Risk factors that compound the ONJ signal include invasive dental procedures (tooth extraction, implant placement), concurrent corticosteroid use, diabetes, and duration of bisphosphonate exposure exceeding 4 years. Current clinical guidance recommends a dental evaluation before starting alendronate and consideration of a drug holiday before elective jaw surgery, though evidence for the protective effect of a 2-month washout remains limited.

Esophageal Adverse Events and Cancer Concerns

Upper gastrointestinal injury was among the earliest FAERS signals for alendronate and remains the most commonly reported category. Reports include esophagitis, esophageal ulcers, esophageal stricture, and in rare cases, esophageal perforation [3]. These events correlate strongly with improper administration, specifically taking the tablet with insufficient water, in a recumbent position, or with other oral medications.

A more controversial signal emerged in 2009 when a nested case-control study using the UK General Practice Research Database suggested a possible doubling of esophageal cancer risk after 5 or more years of oral bisphosphonate use (relative risk 2.24 to 95% CI 1.47 to 3.43) [11]. This prompted the FDA to review FAERS esophageal cancer reports and issue a safety review in 2011. The agency concluded that "the available data do not support a causal relationship between oral bisphosphonate use and the risk of esophageal cancer" but acknowledged the need for continued monitoring [12].

A subsequent large Danish cohort study published in the BMJ involving over 40,000 alendronate users found no increased risk of esophageal or gastric cancer (standardized incidence ratio for esophageal cancer 1.04 to 95% CI 0.71 to 1.48) [13]. The current Fosamax label includes esophageal reactions as warnings and precautions but does not list esophageal cancer as an identified risk. Prescribers should confirm that patients can comply with the specific dosing instructions before initiating therapy.

Severe Musculoskeletal Pain

In January 2008, the FDA issued a safety communication highlighting reports of severe, sometimes incapacitating musculoskeletal pain in patients taking bisphosphonates, including alendronate [14]. This signal was distinct from the mild bone, joint, or muscle pain reported in controlled trials. Onset ranged from one day to several months after starting therapy, and symptoms generally resolved after drug discontinuation.

The FAERS reports described pain that was "severe and incapacitating," with some patients requiring hospitalization or unable to perform daily activities [14]. The FDA noted that the signal was "possibly underrecognized" because musculoskeletal symptoms are common in the osteoporosis population. The Fosamax label was updated in 2008 to include a warning about severe musculoskeletal pain under the Warnings and Precautions section.

This pain is not the same as the acute-phase reaction that occurs in approximately 10% to 30% of patients after their first dose of IV bisphosphonates (flu-like symptoms lasting 24 to 72 hours). The oral alendronate signal involved persistent or recurrent pain without the self-limited fever and malaise pattern. The mechanism remains unclear, though some investigators have proposed direct effects on bone microdamage repair or peripheral nerve sensitization.

Atrial Fibrillation: An Investigated but Unconfirmed Signal

The FIT trial's long-term extension raised an unexpected signal: a higher rate of serious atrial fibrillation events in the alendronate group compared with placebo (1.5% vs. 1.0%, relative risk 1.51 to 95% CI 0.97 to 2.40, P = 0.07) [15]. A 2007 publication of this observation triggered a wave of FAERS scrutiny and epidemiological studies.

The FDA conducted a formal review of the atrial fibrillation signal in 2008, examining FAERS data and published literature. Their conclusion: "FDA believes that the available data do not support a clear association between bisphosphonate use and the rate of serious or non-serious atrial fibrillation" [16]. Several subsequent meta-analyses produced conflicting results. A 2010 meta-analysis by Loke et al. of 4 randomized controlled trials (N = 26,281) found a borderline significant increase in serious atrial fibrillation with bisphosphonate use (odds ratio 1.40 to 95% CI 1.02 to 1.93), but observational studies included in the same analysis showed no association [17].

The current Fosamax label does not carry a specific warning for atrial fibrillation. Clinicians managing patients with pre-existing arrhythmias or cardiac risk factors should be aware of this unresolved signal but should not withhold alendronate therapy solely on this basis, given the strength of fracture prevention data.

FAERS Reporting Patterns and Limitations

Interpreting FAERS data for alendronate requires understanding the system's design constraints. FAERS is a voluntary, spontaneous reporting system. It cannot establish incidence rates, confirm causality, or account for total drug exposure in the population. A single adverse event may generate multiple reports from different sources (patient, prescriber, manufacturer), leading to duplicate entries.

For alendronate specifically, several factors complicate signal interpretation. The drug has been available for over 30 years and is now predominantly prescribed as a generic, which changes reporting behavior. Manufacturer reporting obligations shift when generics enter the market, and generic manufacturers may have different pharmacovigilance infrastructure than the original innovator. Stimulated reporting, where media coverage of a safety concern drives a surge in reports, has been documented for both the AFF and ONJ signals [18].

The FDA's Sentinel System, a distributed data network drawing on electronic health records and insurance claims covering over 100 million patients, has supplemented FAERS analysis for bisphosphonate signals since 2016 [19]. Sentinel active surveillance can calculate incidence rates and compare exposed versus unexposed populations, partially addressing the limitations of passive FAERS reporting. Sentinel analyses have confirmed the AFF duration-response relationship while providing more precise risk estimates than case series or FAERS disproportionality analyses alone.

Risk-Benefit Context and Current Label Status

The 2024 Fosamax prescribing information reflects over two decades of post-market signal accumulation. The Warnings and Precautions section now includes: upper GI adverse reactions, mineral metabolism disturbances (hypocalcemia), musculoskeletal pain, osteonecrosis of the jaw, and atypical subtrochanteric and diaphyseal femoral fractures [2].

Placing these signals in clinical context matters. The Endocrine Society's 2019 guideline on pharmacological management of osteoporosis states: "For most patients at high fracture risk, the benefits of bisphosphonate therapy outweigh the risks for treatment durations of up to 5 years for oral formulations" [20]. This recommendation accounts for the FAERS-identified risks while acknowledging that untreated osteoporosis carries a 40% lifetime fracture probability in white women over age 50 [21].

A 2019 re-analysis of the FIT trial estimated that for every 100 women treated with alendronate for 3 years, the drug prevented 2 hip fractures, 4 clinical vertebral fractures, and 11 any-clinical-fracture events [1]. Against this, the absolute AFF risk is approximately 0.01% to 0.05% per year during the first 5 years, and ONJ risk is approximately 0.1% over the treatment course [6][10].

The practical clinical takeaway from the FAERS record is not that alendronate is unsafe but that its risk profile is duration-dependent. Prescribers should reassess the need for continued therapy at the 5-year mark for oral bisphosphonates, conduct baseline and periodic dental evaluations, confirm proper dosing technique to minimize esophageal events, and counsel patients to report unexplained thigh or groin pain, which may herald an AFF. The recommended starting dose remains alendronate 70 mg orally once weekly for osteoporosis treatment, or 35 mg weekly for prevention, taken first thing in the morning with 6 to 8 ounces of plain water [2].